Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination regimen consists of the anthelmintic praziquantel, iron supplementation, and artemisinin-based combination therapy (ACT). It was evaluated by the DBL - Institute for Health Research and Development in a clinical study (NCT00153140) to assess the impact of treating schistosomiasis, malaria, and iron deficiency on anaemia in school-aged children in Kenya. Praziquantel targets *Schistosoma* parasites by increasing membrane permeability to calcium, leading to parasite paralysis. Iron is provided to address nutritional deficiency and support hemoglobin synthesis. ACT is the standard of care for *Plasmodium falciparum* malaria, utilizing artemisinin derivatives to generate reactive oxygen species that damage parasite components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on praziquantel + iron + artemisinin-based combination therapy.